Regulation of biologics biosimilars and vaccines in India

Introduction

Biologics, biosimilars and vaccines are important categories of modern medicines developed through biological processes. Unlike conventional chemical drugs, biologics are produced using living organisms, cells or biological systems. They include monoclonal antibodies, therapeutic proteins, hormones, blood products and certain advanced therapies.

Biosimilars are biological products demonstrated to be highly similar to an already authorised reference biologic, with no clinically meaningful differences in safety, purity and efficacy. Vaccines are biological preparations designed to stimulate the immune system and provide protection against infectious diseases.

In India, these products are subject to strict regulatory supervision because their development, manufacturing, testing and storage involve complex biological processes. The regulatory framework aims to ensure product quality, safety, efficacy and affordability while encouraging biotechnology innovation.

Legal and regulatory framework in India

The Drugs and Cosmetics Act, 1940, is the principal legislation governing the import, manufacture, distribution and sale of drugs in India. Biologics, biosimilars and vaccines fall within its regulatory framework.

The Drugs Rules, 1945, prescribe requirements relating to licensing, manufacturing standards, testing, labelling and quality control. Schedule M establishes Good Manufacturing Practices requirements for pharmaceutical manufacturing facilities.

The New Drugs and Clinical Trials Rules, 2019, regulate clinical trials and the approval of new drugs. Biological products that fall within the definition of new drugs must satisfy applicable requirements before receiving marketing authorisation.

The Central Drugs Standard Control Organisation (CDSCO), headed by the Drugs Controller General of India (DCGI), performs important regulatory functions. It evaluates applications, grants relevant permissions and supervises compliance with applicable drug regulations.

The Department of Biotechnology (DBT) also plays an important role in regulating biotechnology-related activities through biosafety oversight, particularly where genetically engineered organisms or recombinant technologies are involved.

Regulation of biologics

Biologics require specialised manufacturing and testing because their characteristics depend on complex biological systems. Small changes in cell lines, culture conditions, purification processes or storage conditions may affect product quality.

Manufacturers must demonstrate:

Identity and purity of the biological product.

Biological activity and potency.

Safety and absence of unacceptable contamination.

Consistency between manufacturing batches.

Stability under specified storage conditions.

Compliance with applicable Good Manufacturing Practices.

Biological products may also require specialised testing for sterility, endotoxins, adventitious agents and immunogenicity. Their manufacturing facilities must maintain validated processes and appropriate quality-control systems.

Regulation of biosimilars

India has a specific regulatory framework for biosimilars under the Guidelines on Similar Biologics: Regulatory Requirements for Marketing Authorization in India, 2016, jointly issued by DBT and CDSCO.

These guidelines establish a stepwise comparability approach. A proposed biosimilar is compared with an authorised reference biologic through analytical, functional, non-clinical and, where necessary, clinical studies.

The evaluation generally considers:

Structural and physicochemical similarity.

Biological activity and functional characteristics.

Comparative non-clinical safety.

Comparative clinical safety and efficacy, where required.

Immunogenicity assessment.

Manufacturing consistency and quality assurance.

The objective is not to repeat every study conducted for the original biologic. Instead, the applicant must demonstrate that any identified differences do not create clinically meaningful changes.

Regulation of vaccines

Vaccines are regulated as biological drugs and must satisfy applicable quality, safety and efficacy requirements. Their development may involve preclinical evaluation, clinical trials, manufacturing validation and regulatory review.

The CDSCO examines applications for permission to conduct clinical trials and for marketing authorisation, as applicable. Vaccines must undergo appropriate testing for identity, potency, sterility, purity and stability.

The Central Drugs Laboratory (CDL) and other recognised testing facilities perform regulatory testing functions for relevant biological products. Vaccine manufacturers must also maintain cold-chain controls because temperature variations may affect vaccine potency.

Post-marketing monitoring is important for identifying adverse events following immunisation. The Pharmacovigilance Programme of India and the national adverse events following immunisation surveillance framework contribute to the monitoring of medicine and vaccine safety.

Important case laws

1. Novartis AG v. Union of India (2013)

The Supreme Court interpreted Section 3(d) of the Patents Act, 1970, in relation to pharmaceutical inventions and incremental innovation. Although the case concerned patentability rather than biologics regulation, it is important for understanding the relationship between pharmaceutical innovation, public health and access to medicines.

2. Bayer Corporation v. Union of India (2014)

The Delhi High Court considered issues concerning compulsory licensing under Indian patent law. The judgment is relevant to pharmaceutical regulation because it demonstrates the importance of balancing intellectual property protection with public access to essential medicines, including potentially high-cost biological therapies.

3. Roche Products (India) Pvt. Ltd. v. Drugs Controller General of India (2016)

This litigation involved regulatory and commercial issues concerning biological medicines and biosimilar competition. It is relevant to the development of India's biosimilar market and the distinction between regulatory approval and intellectual property rights. The legal position must be assessed from the specific proceedings rather than treating the case as establishing a general biosimilar approval standard.

4. F. Hoffmann-La Roche Ltd. v. Cipla Ltd. (2009)

The Delhi High Court examined pharmaceutical patent infringement and public interest considerations in relation to an oncology medicine. Although it did not directly determine biologics approval requirements, it illustrates the interaction between pharmaceutical innovation, patent protection and access to treatment.

These cases mainly concern pharmaceutical patents, public interest and medicine access. They should not be understood as direct judicial interpretations of the technical biosimilar approval guidelines.

Regulatory challenges

India faces several challenges in regulating biologics, biosimilars and vaccines. Complex manufacturing processes make quality consistency difficult to maintain. Biosimilar development requires extensive analytical characterisation and reliable comparability studies.

Other challenges include cold-chain infrastructure, pharmacovigilance, counterfeit biological products, affordability and access to specialised testing facilities.

Regulatory authorities must also respond to emerging technologies such as mRNA vaccines, personalised biologics and advanced cell-based therapies. Continuous scientific assessment and international regulatory cooperation are therefore essential.

Conclusion

The regulation of biologics, biosimilars and vaccines in India is based on the Drugs and Cosmetics Act, 1940, the Drugs Rules, 1945, the New Drugs and Clinical Trials Rules, 2019, and the 2016 Similar Biologics Guidelines. CDSCO and DBT perform important regulatory and biosafety functions within their respective jurisdictions. Strict manufacturing controls, analytical comparability, clinical evaluation, pharmacovigilance and cold-chain management help protect public health. Indian judicial decisions concerning pharmaceutical patents and access to medicines further demonstrate the importance of balancing scientific innovation, regulatory accountability and affordable healthcare.